-
公开(公告)号：US09994615B2
公开(公告)日：2018-06-12
申请号：US14379477
申请日：2013-02-19
Inventor： Robert S. Langer , Daniel G. Anderson , Zhen Gu , Alex Arthur Aimetti
Abstract: A glucose binding amphiphilic peptide hydrogel insulin delivery system that is responsive to glucose concentrations under physiological conditions is provided. Insulin is encapsulated in a glucose binding hydrogel, made from self-assembling amphiphilic peptides including a hydrophobic domain including a beta sheet forming region coupled to a charged hydrophilic domain modified to contain a glucose binding segment. The formulations are designed to release insulin as a function of blood glucose level, maintaining the patients' blood glucose level in an optimum range and avoiding both hyper- and hypoglycemia.
-
32.发明授权Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates 有权用于包封细胞和细胞聚集体的多层水凝胶胶囊公开(公告)号：US09555007B2
公开(公告)日：2017-01-31
申请号：US13831250
申请日：2013-03-14
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Arturo Jose Vegas , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup
CPC classification number: A61K35/39 , A61K9/0024 , A61K9/5036 , A61K9/5078 , A61K9/5089 , A61K2035/126 , A61K2035/128 , B01J13/046
Abstract: Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
Abstract translation: 公开了包封直径大于1mm的哺乳动物细胞和任选的无细胞核的生物相容性水凝胶胶囊，其在植入受试者后具有减少的纤维化过度生长。 还公开了治疗受试者疾病的方法，其涉及向受试者施用治疗有效量的所公开的封闭细胞。
-
公开(公告)号：US20250090725A1
公开(公告)日：2025-03-20
申请号：US18952686
申请日：2024-11-19
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Robert S. Langer , Daniel G. Anderson
IPC: A61L27/38 , A61K9/00 , A61K35/12 , A61K35/36 , A61K35/39 , A61K38/02 , A61L27/04 , A61L27/10 , A61L27/16 , A61L27/18 , A61L27/20 , A61L27/34 , A61L27/54 , A61L27/56 , A61L29/14 , C08J7/12
Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
-
公开(公告)号：US20250049713A1
公开(公告)日：2025-02-13
申请号：US18634595
申请日：2024-04-12
Inventor： Sho Toyonaga , Daniel G. Anderson , Theresa Raimondo , Dennis Zheng Shi
IPC: A61K9/127 , A61K9/51 , A61K31/7088
Abstract: The present disclosure provides compositions which enable the delivery of cargo, including therapeutic agents such as RNA, to organs or tissues in addition to the liver, lungs, and spleen, such as brain, heart, kidney, and muscle tissue. More specifically, the compositions comprise a plurality of lipid particles comprising an agent, cationic lipids and ionizable lipid.
-
公开(公告)号：US11802144B2
公开(公告)日：2023-10-31
申请号：US17384460
申请日：2021-07-23
Inventor： Robert Alexander Wesselhoeft , Daniel G. Anderson , Shinichiro Fuse , Brian Goodman , Allen T. Horhota , Raffaella Squilloni
CPC classification number: C07K14/7051 , A61K9/51 , A61K35/17 , C07K16/28 , A61K38/00 , A61K2039/505 , C07K2319/30 , C12N2310/532 , C12N2840/203 , C12N2840/60
Abstract: Circular RNA and transfer vehicles, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes a chimeric antigen receptor (CAR). In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.
-
Patent Agency Ranking
公开(公告)号：US11768262B2
公开(公告)日：2023-09-26
申请号：US16818588
申请日：2020-03-13
Applicant: Massachusetts Institute of Technology
Inventor： Virginia Spanoudaki , Aviad Hai , Alan Pradip Jasanoff , Daniel G. Anderson , Robert S. Langer
IPC: G01R33/36 , H01L29/06 , H01L27/088
CPC classification number: G01R33/36 , H01L29/0673 , H01L27/0886
Abstract: A cross-modal interface includes a multi-modal sensor configured to concurrently receive multiple input signals with each input signal being provided from a different imaging modality and in response thereto providing a single cross-modal output signal to processing circuitry which processes the single cross-modal output signal provided thereto and generates an output comprising information obtained or otherwise derived from each of or a combination of the different imaging modalities.
-
公开(公告)号：US11279928B2
公开(公告)日：2022-03-22
申请号：US15741211
申请日：2016-06-29
Applicant: Massachusetts Institute of Technology
Inventor： Hao Yin , Daniel G. Anderson , Robert Samuel Langer
Abstract: The disclosure relates to compositions comprising and methods for chemical modification of single guide RNA (sgRNA), tracrRNA and/or crRNA used individually or in combination with one another or Cas system components. Compositions comprising modified ribonucleic acids have been designed with chemical modification for even higher efficiency as unmodified native strand of sgRNA. Administration of modified ribonucleic acids will allow decreased immune response when administered to a subject, increased stability, increased editing efficiency and facilitated in vivo delivery of sgRNA via various delivery platforms. The disclosure also relates to methods of decreasing off-target effect of CRISPR and a CRISPR complex.
-
公开(公告)号：US11090413B2
公开(公告)日：2021-08-17
申请号：US16289390
申请日：2019-02-28
Inventor： Arturo Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
IPC: A61L29/08 , A61K47/36 , A61K9/48 , A61K35/39 , C08B37/00 , A61K9/00 , A61K9/50 , A61L31/10 , A61L33/08 , C07D487/04 , C12N5/00 , C12N5/071
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
-
公开(公告)号：US20210069100A1
公开(公告)日：2021-03-11
申请号：US17024148
申请日：2020-09-17
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup , Arturo Jose Vegas
Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
公开(公告)号：US10814115B2
公开(公告)日：2020-10-27
申请号：US13728300
申请日：2012-12-27
Inventor： Carlo Giovanni Traverso , Avraham D. Schroeder , Baris Erinc Polat , Carl Magnus Schoellhammer , Daniel Blankschtein , Daniel G. Anderson , Robert S. Langer
Abstract: The present disclosure provides devices and uses thereof. A devices disclosed herein comprises a plurality of microneedles adapted to protrude from the device. In some embodiments, a device is dimensioned and constructed to carry a payload, so that the payload can be delivered to an internal tissue of a subject or through a wall of a vessel after interaction with microneedles. In some embodiments, devices can be used for oral or intravenous administration. In some embodiments, devices can be used for implantation such as vaginal, rectal, urethral or bladder suppository or pessary.
-
-
-
-
-
-
-
-
-
Search Results
104
records
(took 0.027 seconds)
